CEVEC Pharmaceuticals
- Company typePrivate
- Founded2003
- HeadquartersKöln, Germany
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
CEVEC Pharmaceuticals firmographics
Firmographics- Name
- CEVEC Pharmaceuticals
- Website
- https://cevec.com
- Company type
- Private
- Founded year
- 2003
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
CEVEC Pharmaceuticals industry classification
Industry- Product category
- Cell Line Development for Biomanufacturing
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN)
Keywords
Where CEVEC Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Köln
- HQ country
- Germany
- HQ region
- Europe
Markets served
CEVEC Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
CEVEC Pharmaceuticals product offering
Product offeringCore offering
CEVEC develops and supplies proprietary stable producer cell line platforms that enable biopharmaceutical manufacturers to produce viral vectors and complex therapeutic proteins at scale. Its core products — the ELEVECTA™ AAV producer cell line platform, the CAP™ adenovirus producer cell line, and the GOCHO™ expression platform for human-glycosylated monoclonal antibodies and therapeutic proteins — replace traditional transient transfection workflows with stable, single-clone manufacturing processes suitable for clinical and commercial bioproduction.
Product overview
CEVEC Pharmaceuticals, acquired by Cytiva in 2022, offers a portfolio of cell line development products and services for biopharmaceutical manufacturing. The core offerings include the ELEVECTA™ producer cell line platform for AAV-based gene therapy production, the GOCHO™ platform for monoclonal antibody and protein production cell line development, and the CAP™ Ad cell line for adenovirus manufacturing. These platforms work together to provide end-to-end viral vector solutions addressing industry challenges around scalability, batch consistency, and supply chain bottlenecks in advanced therapy manufacturing.
Differentiator
Problem solved
Functional benefit
Brands
- ELEVECTA™: Producer cell line platform for AAV-based gene therapy manufacturing, addressing batch-to-batch variability from transient transfection methods, GMP-grade plasmid DNA supply chain bottlenecks, and scalability limitations.
Products and services
- ELEVECTA™ Producer Cell Line Platform A stable producer cell line platform for adeno-associated virus (AAV) manufacturing designed to replace traditional transient transfection with scalable, reproducible, single-clone AAV production for gene therapy developers, CDMOs, and biopharmaceutical manufacturers.
- CAP™ Ad Cell Line A stable producer cell line for adenoviral vector manufacturing, providing scalable and reproducible upstream production of adenovirus for cell and gene therapy, vaccine, and oncolytic applications.
- GOCHO™ Cell Line Platform An expression platform based on stable human cell lines that produce therapeutic proteins and monoclonal antibodies with human glycosylation patterns, intended for biopharmaceutical developers requiring human-compatible post-translational modifications.
Quantifiable outcome
- Eliminates batch-to-batch variability inherent in transient transfection methods
- +2 more outcomes
Companies that use CEVEC Pharmaceuticals
Customer profileSegments3 records
Ideal customer profiles1 record
CEVEC Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
CEVEC Pharmaceuticals partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- CytivacoreCytiva acquired CEVEC Pharmaceuticals in 2022 to strengthen its cell line development capabilities. The acquisition expanded Cytiva's portfolio to include CEVEC's ELEVECTA™ producer cell line platform for AAV-based gene therapy manufacturing and CAP™ Ad cell line for adenovirus production.
Scale indicators2 records
Recent moves7 records
Expansion highlights4 records
CEVEC Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- GenScript ProBio: GenScript ProBio provides cell line development services, viral vector manufacturing, and gene therapy CDMO services for biopharmaceutical customers. Directly comparable to CEVEC's offerings around producing host cell lines and viral vectors for therapeutic manufacturing.
- Repligen Corporation: Repligen provides bioprocessing tools and technologies used in viral vector and gene therapy manufacturing, including filtration, chromatography, and process analytics. Comparable as a specialized bioprocessing technology provider serving gene therapy CDMOs and developers.
- Cobra Biologics (Charles River Laboratories): Cobra Biologics, now part of Charles River, provides plasmid DNA, viral vector, and cell line development services for gene therapy and vaccine manufacturers. Operates a directly comparable service offering to CEVEC's producer cell line platform across the AAV/adenovirus manufacturing space.
Broad incumbents
- Lonza Cell & Gene Technologies: Lonza is the largest contract development and manufacturing organization for cell and gene therapies, including viral vector manufacturing services. As a broad incumbent in viral vector process development, Lonza competes in offering end-to-end AAV and lentiviral production platforms similar to CEVEC's stable producer cell line approach.
- WuXi Biologics: WuXi Biologics is a leading global CDMO with extensive capabilities in cell line development, biologics manufacturing, and viral vector services. Operates in similar end markets as CEVEC with both upstream process development platforms and full manufacturing services.
- FujiFilm Diosynth Biotechnologies: FujiFilm Diosynth Biotechnologies is a major CDMO with significant gene therapy and viral vector manufacturing capacity. Comparable to CEVEC in addressing the upstream viral vector production needs of gene therapy customers, including AAV and lentiviral platforms.
- Catalent (Paragon Gene Therapy): Catalent's Paragon Gene Therapy business provides viral vector manufacturing for AAV and lentivirus, and offers related process development technologies for gene therapy developers. Directly comparable as a services and technology provider for viral vector manufacturing customers.
- Thermo Fisher Scientific (Patheon / Olin): Thermo Fisher offers viral vector and cell line development services through its pharma services division, providing both manufacturing services and supporting cell line technologies for gene therapy and biologics. Comparable to CEVEC as a top-tier bioprocessing tools and services provider serving AAV/mAb manufacturers.
- MilliporeSigma (Sigma-Aldrich / Merck KGaA Life Science): MilliporeSigma is the life science arm of Merck KGaA, offering cell lines, viral vector production technologies, and bioprocessing consumables. Overlaps with CEVEC in upstream process development for AAV/adenovirus and in mAb cell line development.
- Sartorius Stedim Biotech: Sartorius Stedim Biotech is a leading supplier of bioprocess equipment, consumables, and cell line development services for biologics and advanced therapies. Directly comparable to Cytiva/CEVEC's bioprocessing footprint serving both mAb and viral vector manufacturers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
CEVEC Pharmaceuticals social profiles
Digital presenceCEVEC Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
CEVEC Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles2 records
CEVEC Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds5 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CEVEC Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CEVEC Pharmaceuticals
What does CEVEC Pharmaceuticals do?
CEVEC develops and supplies proprietary stable producer cell line platforms that enable biopharmaceutical manufacturers to produce viral vectors and complex therapeutic proteins at scale. Its core products — the ELEVECTA™ AAV producer cell line platform, the CAP™ adenovirus producer cell line, and the GOCHO™ expression platform for human-glycosylated monoclonal antibodies and therapeutic proteins — replace traditional transient transfection workflows with stable, single-clone manufacturing processes suitable for clinical and commercial bioproduction.
When was CEVEC Pharmaceuticals founded?
CEVEC Pharmaceuticals was founded in 2003. It employs 11 to 50 people.
Where is CEVEC Pharmaceuticals based?
CEVEC Pharmaceuticals is headquartered in Köln, Germany, in the Europe region.
Who are CEVEC Pharmaceuticals's main competitors?
Direct peers on record are GenScript ProBio, Repligen Corporation and Cobra Biologics (Charles River Laboratories). Broad incumbents are Lonza Cell & Gene Technologies, WuXi Biologics, FujiFilm Diosynth Biotechnologies, Catalent (Paragon Gene Therapy), Thermo Fisher Scientific (Patheon / Olin), MilliporeSigma (Sigma-Aldrich / Merck KGaA Life Science) and Sartorius Stedim Biotech.
Does CEVEC Pharmaceuticals have an API?
No public API is recorded for CEVEC Pharmaceuticals.
What industry is CEVEC Pharmaceuticals in?
CEVEC Pharmaceuticals's product category is Cell Line Development for Biomanufacturing. Its primary akta.pro industry code is HLAAACAN, Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream). Its NAICS code is 325414 and its SIC code is 2836.